- Home
- ARVN vs ECPG Comparison
ARVN vs ECPG Comparison
Compare ARVN & ECPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARVN
- ECPG
- Stock Information
- Founded
- ARVN 2015
- ECPG 1998
- Country
- ARVN United States
- ECPG United States
- Employees
- ARVN N/A
- ECPG N/A
- Industry
- ARVN Biotechnology: Pharmaceutical Preparations
- ECPG Finance Companies
- Sector
- ARVN Health Care
- ECPG Finance
- Exchange
- ARVN Nasdaq
- ECPG Nasdaq
- Market Cap
- ARVN 1.2B
- ECPG 1.2B
- IPO Year
- ARVN 2018
- ECPG 1999
- Fundamental
- Price
- ARVN $7.02
- ECPG $34.28
- Analyst Decision
- ARVN Buy
- ECPG Strong Buy
- Analyst Count
- ARVN 13
- ECPG 3
- Target Price
- ARVN $34.42
- ECPG $62.67
- AVG Volume (30 Days)
- ARVN 3.5M
- ECPG 350.4K
- Earning Date
- ARVN 05-06-2025
- ECPG 05-07-2025
- Dividend Yield
- ARVN N/A
- ECPG N/A
- EPS Growth
- ARVN N/A
- ECPG N/A
- EPS
- ARVN N/A
- ECPG N/A
- Revenue
- ARVN $263,399,999.00
- ECPG $1,316,361,000.00
- Revenue This Year
- ARVN N/A
- ECPG $21.62
- Revenue Next Year
- ARVN $7.99
- ECPG $10.12
- P/E Ratio
- ARVN N/A
- ECPG N/A
- Revenue Growth
- ARVN 235.54
- ECPG 7.66
- 52 Week Low
- ARVN $6.88
- ECPG $31.54
- 52 Week High
- ARVN $41.34
- ECPG $51.77
- Technical
- Relative Strength Index (RSI)
- ARVN 23.50
- ECPG 36.97
- Support Level
- ARVN $8.51
- ECPG $34.57
- Resistance Level
- ARVN $9.17
- ECPG $36.68
- Average True Range (ATR)
- ARVN 0.55
- ECPG 1.41
- MACD
- ARVN -0.05
- ECPG 0.57
- Stochastic Oscillator
- ARVN 5.24
- ECPG 53.31
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About ECPG Encore Capital Group Inc
Encore Capital Group Inc is an international specialty finance company. It provides debt recovery solutions for consumers and property owners across a broad range of financial assets. The company purchase portfolios of defaulted consumer receivables at deep discounts to face value and manages them by working with individuals as the consumer repay their obligations and work toward financial recovery. Encore has only a reportable segment being portfolio purchasing and recovery.